Rabies ig ht&sol human im/sc
Products billed under this code include Kedrab.
Payment limit per 150 IU, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Kedrab.
Payment limit per 150 IU, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Kedrab | Kedrion Biopharma Inc | 76125-0150-02 | 2 | $501.088 |
| Kedrab | Kedrion Biopharma Inc | 76125-0150-10 | 10 | $2,505.44 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $250.544 | +$7.346 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted September 17, 2026 |
| 3Q26 | $243.198 | +$1.021 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted September 15, 2026 |
| 2Q26 | $242.177 | +$2.044 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted September 15, 2026 |
| 1Q26 | $240.133 | +$17.887 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted September 15, 2026 |
| 4Q25 | $222.246 | −$14.854 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted September 8, 2026 |
| 3Q25 | $237.10 | −$4.048 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted March 10, 2026 |
| 2Q25 | $241.148 | −$9.376 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted March 10, 2026 |
| 1Q25 | $250.524 | −$14.981 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted December 19, 2025 |
| 4Q24 | $265.505 | +$5.07 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 11, 2025 |
| 3Q24 | $260.435 | +$9.455 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 11, 2025 |
| 2Q24 | $250.98 | −$5.325 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted March 11, 2025 |
| 1Q24 | $256.305 | +$5.814 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted December 19, 2024 |
| 4Q23 | $250.491 | +$16.401 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted October 10, 2024 |
| 3Q23 | $234.09 | +$2.064 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 5, 2024 |
| 2Q23 | $232.026 | −$15.26 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted February 23, 2024 |
| 1Q23 | $247.286 | +$11.622 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted December 6, 2023 |
| 4Q22 | $235.664 | −$5.538 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 22, 2023 |
| 3Q22 | $241.202 | +$17.588 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 9, 2023 |
| 2Q22 | $223.614 | −$16.305 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted December 14, 2022 |
| 1Q22 | $239.919 | −$32.418 | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 8, 2022 |
| 4Q21 | $272.337 | – | 150 IU | Rabies ig ht&sol human im/sc | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.